Brief: Viracta Therapeutics Announces First Patient Dosed In Phase 1B/2 Trial Of Patients With Advanced Epstein-Barr Virus-Positive Solid Tumors
31/01/2022 13:32
Jan 31 (Reuters) - Viracta Therapeutics Inc VIRX.O :
* VIRACTA THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN
PHASE 1B/2
TRIAL OF NANA-VAL IN PATIENTS WITH ADVANCED EPSTEIN-BARR
VIRUS-POSITIVE SOLID TUMORS
* VIRACTA THERAPEUTICS INC - PRELIMINARY SAFETY AND EFFICACY
DATA
ANTICIPATED IN SECOND HALF OF 2022
Source text for Eikon: ID:nPn8HxSlpa
Further company coverage: VIRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Viracta Therapeutics
See all newsBrief: Viracta Therapeutics Announces Wind Down Of Operations
Brief: Viracta Therapeutics Announces Closure Of Naval-1 Clinical Trial And Exploration Of Strategic Alternatives
Brief: Viracta Therapeutics Receives Notice Of Non-Compliance From Nasdaq
Viracta Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Viracta Therapeutics Reports Q3 2024 Financial Results And Provides Business Update